




Welcome to GSK

# Marta Kovatcheva, PhD

Assistant Investigator, Cell Plasticity and Aging, IFOM  
What can we help you find today?

[Cancer Biology](#)



Lab Phone

212-639-2354

Email

[KovatchM@sloankettering.edu](mailto:KovatchM@sloankettering.edu)

Dissertation

[New roles for old proteins: MDM2 and ATRX drive the transition from quiescence to senescence \(2017\)](#)

Start Year

2010

End Year

2017

Education

University of Toronto

## Fellowships

[Grayer Fellowship](#) (2012-2013)

[Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship](#) (2011-2012)

## Publications

[Kovatcheva M, Klein ME, Tap WD, Koff A. \(2017\) Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. \*Mol Cell Oncol\*. 5, e1384882. PMID: PMC5791849. \[Available on 2018-11-07\]](#)

[Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. \(2018\) CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. \*Cancer Cell\*. \[Epub ahead of print\]](#)

[Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, Koff A. \(2017\) ATRX is a regulator of therapy induced senescence in human cells. \*Nat Commun\*. 8, 386. PMID: PMC5577318](#)

[Kovatcheva M, Liu DD, Dickson MA, Klein ME, O'Connor R, Wilder FO, Succi ND, Tap WD, Schwartz GK, Singer S, Crago AM, Koff A. \(2015\) MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. \*Oncotarget\*. 6, 8226-43. PMID: PMC4480747.](#)

[View a full listing of Marta Kovatcheva's journal articles.](#)

© 2026 Louis V. Gerstner Jr. Graduate School of Biomedical Sciences Memorial Sloan Kettering Cancer Center